I think you are right. Very few things in life sell themselves and to think that a small biotech can compete with a multinational pharmaceutical company on the sales side is silly. Irrespective of what price I eventually sell the bulk of my ARIAD holdings I do think I will look to exit at some point after Pona results are in, 113 results are in but before we starting selling Pona. I mean once you start selling the product all the good news is baked in and the only surprise is normally bad.